NKTR — Nektar Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.07bn
- $1.89bn
- $55.23m
Annual income statement for Nektar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 102 | 92.1 | 90.1 | 98.4 | 55.2 |
| Cost of Revenue | |||||
| Gross Profit | 77 | 70.4 | 56.4 | 67.7 | 55.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 548 | 468 | 354 | 204 | 195 |
| Operating Profit | -446 | -376 | -264 | -105 | -140 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -523 | -365 | -276 | -119 | -155 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -524 | -368 | -276 | -119 | -155 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -524 | -368 | -276 | -119 | -164 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -524 | -368 | -276 | -119 | -164 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -42.9 | -22.4 | -15.2 | -9.85 | -9.37 |